神経変性疾患市場規模、シェア、成長分析、薬剤クラス別、適応疾患別、投与経路別、エンドユーザー別、地域別 - 産業予測、2025年～2032年

神経変性疾患の世界市場規模は2023年に526億米ドルと評価され、2024年の563億9,000万米ドルから2032年には983億4,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは7.2％で成長する見通しです。

世界の神経変性疾患市場は、診断・治療技術の進歩、政府資金の増加、患者層の進化に後押しされ、大きな成長を遂げています。特にアルツハイマー、パーキンソン病、ALSなどの疾患では、革新的なヘルスケアインフラと的を絞った調査イニシアティブが脚光を浴びています。治療効果と診断精度の向上は、AIと機械学習技術を統合して脳スキャンを分析し、疾患の進行を特定し、投薬反応を調整することで、業界を再構築しています。先進医療プラットフォームの出現は、患者と神経科医間のリアルタイムの遠隔モニタリングとシームレスなデータ交換をサポートし、タイムリーな介入を促進します。さらに、持続可能性とコスト効率に重点を置くことで、ポータブルでエネルギー効率の高い診断ツールの設計が推進されています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• ケーススタディ
• 顧客購買行動分析

神経変性疾患市場規模：薬剤クラス別& CAGR（2025-2032）

• 市場概要
• 免疫調節剤
• インターフェロン
• 脱炭酸酵素阻害剤
• ドーパミン作動薬
• その他

神経変性疾患市場規模：適応疾患別& CAGR（2025-2032）

• 市場概要
• 多発性硬化症
• パーキンソン病
• アルツハイマー病
• 脊髄性筋萎縮症（SMA）
• その他

神経変性疾患市場規模：投与経路別& CAGR（2025-2032）

• 市場概要
• 経口
• 注射
• 経皮

神経変性疾患市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院薬局
• 小売薬局
• オンライン薬局

神経変性疾患市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd
• Merck & Co., Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB S.A
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S

結論と提言

Global Neurodegenerative Disease Market size was valued at USD 52.6 billion in 2023 and is poised to grow from USD 56.39 billion in 2024 to USD 98.34 billion by 2032, growing at a CAGR of 7.2% during the forecast period (2025-2032).

The global neurodegenerative disease market is experiencing significant growth, propelled by advancements in diagnostic and treatment technologies, increased government funding, and evolving patient demographics. Innovative healthcare infrastructures and targeted research initiatives are gaining prominence, particularly for conditions such as Alzheimer's, Parkinson's, and ALS. Enhancements in treatment efficacy and diagnostic accuracy are reshaping the industry, with the integration of AI and machine learning techniques to analyze brain scans, identify disease progression, and tailor medication responses. The emergence of advanced medical platforms supports real-time remote monitoring and seamless data exchange between patients and neurologists, facilitating timely interventions. Furthermore, a focus on sustainability and cost-efficiency is driving the design of portable, energy-efficient diagnostic tools, ensuring greater accessibility in underserved areas while enabling continuous patient evaluation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Neurodegenerative Disease market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Neurodegenerative Disease Market Segments Analysis

Global Neurodegenerative Disease Market is segmented by Drug Class, Disease Indication, Route of Administration, End User and region. Based on Drug Class, the market is segmented into Immunomodulator, Interferons, Decarboxylase Inhibitors, Dopamine Agonists and Others. Based on Disease Indication, the market is segmented into Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Spinal Muscular Atrophy (SMA) and Others. Based on Route of Administration, the market is segmented into Oral, Injection and Transdermal. Based on End User, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Neurodegenerative Disease Market

Advancements in diagnostic technologies such as PET scans, biomarker-focused blood tests, and AI-driven neuroimaging have significantly improved the early and accurate identification of neurodegenerative diseases. These innovations enhance patient management and treatment outcomes through timely detection. Consequently, the global market is experiencing growth across diagnostic, therapeutic, and monitoring sectors, driven by these developments. This surge is further fostering an increase in clinical trials and research investments, as the focus on effective solutions for neurodegenerative conditions intensifies. As a result, the landscape of the neurodegenerative disease market is evolving, reflecting the urgent need for improved therapies and diagnostics.

Restraints in the Global Neurodegenerative Disease Market

The Global Neurodegenerative Disease market faces significant challenges due to the high costs associated with advanced therapies, which often include expensive medications, continuous care, and specialized diagnostic tools. These financial barriers particularly affect patients in low- and middle-income countries, limiting their access to innovative treatments such as gene therapy and monoclonal antibodies. The burden of substantial out-of-pocket expenses hampers the adoption of these therapies, leading to delays in early intervention. Consequently, this situation adversely affects the long-term health outcomes for patients across various regions, exacerbating the existing disparities in healthcare accessibility and treatment effectiveness.

Market Trends of the Global Neurodegenerative Disease Market

The global neurodegenerative disease market is witnessing a significant trend driven by the integration of artificial intelligence (AI) in diagnostics. This technological advancement enables early detection of conditions like Alzheimer's by analyzing patient histories, blood biomarkers, and brain scans with remarkable precision. As AI algorithms enhance diagnosis speed and clinical accuracy, healthcare providers are increasingly adopting these tools, resulting in a more proactive approach to neurodegenerative disease management. This shift not only facilitates timely interventions but also fosters improved patient outcomes, thereby solidifying AI's role as a pivotal catalyst for growth in the neurodegenerative diseases market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Neurodegenerative Disease Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Immunomodulator
• Interferons
• Decarboxylase Inhibitors
• Dopamine Agonists
• Others

Global Neurodegenerative Disease Market Size by Disease Indication & CAGR (2025-2032)

• Market Overview
• Multiple Sclerosis
• Parkinson's Disease
• Alzheimer's Disease
• Spinal Muscular Atrophy (SMA)
• Others

Global Neurodegenerative Disease Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injection
• Transdermal

Global Neurodegenerative Disease Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Global Neurodegenerative Disease Market Size & CAGR (2025-2032)

• North America (Drug Class, Disease Indication, Route of Administration, End User)
  • US
  • Canada
• Europe (Drug Class, Disease Indication, Route of Administration, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Disease Indication, Route of Administration, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Disease Indication, Route of Administration, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Disease Indication, Route of Administration, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Orion Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ACADIA Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations